Medigen Biotechnology Corporation (3176) AI Stock Analysis

Medigen Biotechnology Corporation

(TPEx:3176)

Select Model

Rating:38Underperform

Price Target:$30.00▼(-0.33% Downside)

Action:initiatedcoverage

Date:11/10/26

The overall score is severely depressed by the company's inability to generate profits, which is reflected across all evaluated components. The most significant factor is the weak financial performance, where strong revenue growth is overshadowed by persistent net losses and negative free cash flow. This fundamental weakness is confirmed by a bearish technical outlook, with the stock in a clear downtrend and weak momentum. The negative P/E ratio further underscores the lack of earnings. The successful balance sheet deleveraging is a positive but insufficient to offset the core profitability and cash flow challenges.

Positive Factors

Stable Gross MarginA consistently healthy gross margin indicates that the company has preserved economics in its products and therapies despite revenue volatility. This provides a foundation for future operating leverage if sales recover, although current losses show that gross profit is not yet sufficient to cover the broader cost base.

Negative Factors

Volatile and Declining RevenueRepeated swings in annual revenue make the company’s commercial trajectory difficult to rely on over the next several quarters. The approximately 25% decline in 2025 suggests that recent recovery was not yet durable, limiting operating leverage and making sustained investment in therapies more challenging.

Medigen Biotechnology Corporation (3176) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 4.22B
Dividend Yield: ―
Average Volume (3M): 628.92K
Price to Earnings (P/E): -16.6
Beta (1Y): 0.40
Revenue Growth: 1.11%
EPS Growth: -94.39%
Country: TW
Employees: 67
Sector: General
Sector Strength: 55
Industry: Biotechnology

Medigen Biotechnology Corporation Business Overview & Revenue Model

Company Description

Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural kil...

Medigen Biotechnology Corporation Financial Statement Overview

Summary

Financial performance reflects a company in early-stage recovery. Revenue growth is strong and gross margins have stabilized at a healthy 54%, but the company remains unprofitable with negative EBIT and net income. The balance sheet has been successfully deleveraged, reducing risk, and operating cash flow has turned positive. However, free cash flow remains negative, and the inability to convert revenue into sustainable profits is a major concern, resulting in a below-average score.

Income Statement

35Negative

Balance Sheet

55Neutral

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.32B	1.58B	1.37B	1.16B	1.06B	3.92B
Gross Profit	624.60M	857.73M	753.76M	617.33M	73.07M	2.53B
EBITDA	-42.55M	18.64M	98.91M	-1.04B	-1.64B	1.35B
Net Income	-252.36M	-108.80M	-204.69M	-561.30M	-675.87M	-52.61M
Balance Sheet
Total Assets	6.90B	6.18B	6.71B	8.53B	9.98B	8.20B
Cash, Cash Equivalents and Short-Term Investments	2.72B	2.50B	2.59B	4.59B	5.07B	3.00B
Total Debt	1.72B	952.79M	1.07B	2.91B	2.81B	1.04B
Total Liabilities	2.19B	1.46B	1.67B	3.53B	3.51B	1.77B
Stockholders Equity	1.48B	1.55B	1.58B	1.59B	2.19B	2.39B
Cash Flow
Free Cash Flow	-464.55M	-22.41M	-20.76M	-545.42M	-1.28B	372.90M
Operating Cash Flow	-44.62M	49.03M	37.92M	-503.52M	-1.13B	517.45M
Investing Cash Flow	-468.51M	44.34M	903.30M	497.66M	-692.67M	-369.75M
Financing Cash Flow	579.70M	-157.26M	-1.77B	193.15M	1.72B	-209.29M

Medigen Biotechnology Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:3176 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6794	40Underperform	TWD 4.10B	-34.13	―	―	-48.98%	-2.09%
TW:3176	38Underperform	TWD 4.62B	-16.65	―	―	1.11%	-94.39%
TW:4726	35Underperform	TWD 4.76B	-12.16	―	―	52.81%	38.53%

* General Sector Average

Performance Comparison

TW:3176 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:3176	Medigen Biotechnology Corporation	30.10	0.20	0.67%
TW:4726	Mycenax Biotech Inc.	22.40	-11.25	-33.43%
TW:6610	TWi Biotechnology, Inc	17.50	-19.34	-52.50%
TW:6634	Sinew Pharma, Inc.	63.20	22.70	56.05%
TW:6794	UnicoCell Biomed Co., Ltd.	64.80	-6.20	-8.73%
TW:7902	Uwell Biopharma Inc.	25.45	-2.15	-7.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Medigen Biotechnology Corporation AI Stock Analysis